23andMe Launches Discover23 for Enhanced Research Collaboration
23andMe Holding Co. (NASDAQ: ME), a leader in the field of human genetics, has recently unveiled Discover23, an innovative research platform designed to facilitate secure access to the extensive research cohort 23andMe has built. This platform promises a seamless experience for biopharma collaborators, powered by Lifebit's renowned Trusted Research Environment (TRE), which prioritizes data security and integrity.
A New Era in Genetic Research
With Discover23, authorized partners will have the ability to conduct sophisticated analyses on over 1,000 disease and condition cohorts. This research is backed by more than 4.7 billion phenotypic data points meticulously curated by the expert scientists at 23andMe. These genome-wide association studies (GWAS) are set to shed new light on the genetic factors that underlie various health conditions, driving biomedical research forward.
The Power of Data
Discover23 provides a unique opportunity for researchers to explore over 172 million genetic variants. These variants are analyzed in conjunction with billions of pieces of phenotypic data collected from consenting participants in the 23andMe research program. Approximately 84% of the company's 15 million customers have opted into this program, creating a vast reservoir of information that partners can leverage to identify novel biological mechanisms behind diseases and discover promising new drug targets.
Secure and Ethical Research Practices
23andMe has taken substantial steps to ensure participant privacy and ethical research practices. All customers in the research program have the option to consent, with their data being handled under strict safeguards. An Institutional Review Board oversees the program, ensuring compliance with high ethical standards. Only aggregated data devoid of personal identifiers is used, providing an additional layer of security for participants' privacy while allowing invaluable insights into genetic research.
Expert Insights from Leadership
CEO Anne Wojcicki expressed her enthusiasm for this advancement, stating, "We are excited to empower experts at the forefront of biomedical research with access to insights and expertise through Discover23. We believe that facilitating access to these insights can potentially lead to the discovery of new and more effective treatments."
Collaboration with Lifebit
Dr. Maria Dunford, CEO of Lifebit, echoed this sentiment, emphasizing the commitment both companies share towards advancing drug development and precision medicine. She noted the importance of robust security measures in handling sensitive healthcare data, highlighting that their collaboration aims to create a safe, federated platform for analyzing data where it resides.
Engagement Opportunities for Partners
Partners interested in Discover23 and the range of analytical services offered by 23andMe are encouraged to get in touch for more information. The teams from 23andMe and Lifebit will be present at the upcoming JPM Healthcare Conference, where more about Discover23 will be shared. This conference serves as a vital platform for discussing collaborations that can significantly impact research and patient outcomes.
About 23andMe and Lifebit
23andMe is dedicated to transforming healthcare through genetics, positioning itself as a pivotal company in ensuring a healthier future through data-driven insights. Lifebit stands as a global leader in managing genomics and health data solutions, committed to enhancing the way sensitive biomedical data is utilized in research.
Frequently Asked Questions
What is Discover23?
Discover23 is a research platform launched by 23andMe to facilitate access to genetic data for biopharma collaborators, backed by Lifebit's security technology.
How does Discover23 ensure participant privacy?
Participant privacy is safeguarded by stripping personal identifiers from data and requiring consent from participants, with oversight by an Institutional Review Board.
What kind of data can researchers access through Discover23?
Researchers can access analysis-ready GWAS conducted on various disease cohorts, analyzing over 172 million genetic variants linked to billions of phenotypic data points.
What are the benefits for biopharma collaborators using Discover23?
Collaborators can identify new drug targets, enhance research programs, and ultimately contribute to the development of more effective treatments.
How can organizations partner with 23andMe?
Interested organizations can reach out for details on collaboration opportunities, particularly at events like the JPM Healthcare Conference.
